CN1569085A - Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis - Google Patents
Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis Download PDFInfo
- Publication number
- CN1569085A CN1569085A CN 03145967 CN03145967A CN1569085A CN 1569085 A CN1569085 A CN 1569085A CN 03145967 CN03145967 CN 03145967 CN 03145967 A CN03145967 A CN 03145967A CN 1569085 A CN1569085 A CN 1569085A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- weight
- processed
- radix
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis, wherein the composition comprises, plantain seeds, prepared Sichuan aconite root, prepared wild aconite root, frankincense, myrrh, rhizoma corydalis, safflower, gastrodia tuber, gen-seng, notoginseng, buthus martensi kirsch, centipede, atractylodes rhizome, eucommia bark.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly relate to a kind of pharmaceutical composition for the treatment of rheumatism atrophic arthritis.
Background technology
Rheumatism is that a kind of common clinical, frequently-occurring disease, disease cycle are longer, and the clinical symptoms performance is various, the stubborn disease that the treatment phase is long.Because of such disease cause of disease, pathogenesis more complicated, clinical be marginality, multidisciplinary performance more, the limitation of Chinese medicine itself and to the heterogeneity of the understanding of this type of disease is in addition all controlled and the clinical research work of such pathological changes is brought certain difficulty to clinical dialectical executing.In motherland's medical science, rheumatism is collectively referred to as " numbness " disease.A Plain Questions of Huangdi's Internal Classic numbness opinion piece of writing the 43 is said: " wind, cold, wet three gas are assorted extremely, close and be numbness also ".Domination of wind then is a migratory arthralgia, and domination of cold then is an arthralgia aggravated by cold, and domination of damp pathogen then is an arthralgia caused mainly by damp.That this disease Therapeutic Principle dispels the wind, wins is wet, warming the meridian, by cold, make wind, cold, wet three gas are dispeled and disease is separated.
Technology contents
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of rheumatism atrophic arthritis.
The crude drug of pharmaceutical composition of the present invention is formed and proportioning following (by weight):
Semen Strychni(processed) 20-100 weight portion Radix Aconiti Preparata 20-80 weight portion
Radix Aconiti Kusnezoffii Preparata 20-80 weight portion Olibanum (processed) 10-40 weight portion
Myrrha (processed) 10-40 weight portion Rhizoma Corydalis 200-300 weight portion
The parasitic 20-60 weight portion of Flos Carthami 10-50 weight portion
Radix Stephaniae Tetrandrae 10-50 weight portion Rhizoma Gastrodiae 10-50 weight portion
Radix Ginseng 10-40 weight portion Radix Notoginseng 10-40 weight portion
Scorpio 20-80 weight portion Scolopendra 8-30 weight portion
Rhizoma Atractylodis 8-30 weight portion Cortex Eucommiae 8-30 weight portion
The optimum ratio of pharmaceutical composition crude drug of the present invention is:
Semen Strychni(processed) 60 weight portion Radix Aconiti Preparatas 50 weight portions
Radix Aconiti Kusnezoffii Preparata 50 weight portion Olibanum (processed)s 25 weight portions
Myrrha (processed) 25 weight portion Rhizoma Corydalis 100 weight portions
Parasitic 40 weight portions of Flos Carthami 30 weight portions
Radix Stephaniae Tetrandrae 30 weight portion Rhizoma Gastrodiaes 30 weight portions
Radix Ginseng 25 weight portion Radix Notoginseng 25 weight portions
Scorpio 50 weight portion Scolopendras 20 weight portions
The Rhizoma Atractylodis 20 weight portion Cortexs Eucommiae 20 weight portions
Above-mentioned ten Six-element medical materials, Semen Strychni are concocted, fried stir-baking in sand all can, can not cross and give birth to or cross water.Radix Aconiti Preparata, Radix Aconiti Kusnezoffii Preparata dry after 3 hours with decocting in water again and are used as medicine.Olibanum, Myrrha processed with vinegar, with other drug routinely technology be ground into fine powder, add pharmaceutically acceptable excipient and make clinical acceptable forms, as pill, tablet, oral liquid, capsule, granule etc.
Pharmaceutical composition of the present invention has expelling wind and cold, and numbness, the function of the meridian dredging, the pain that relieves the pain are exempted from dehumidifying; To treatment rheumatism, rheumatoid arthritis, ankylosing spondylitis, aseptic osteonecrosis, various rheumatism effects such as intervertebral disk hernia, sciatica, various bone matrix hyperplasia, scapulohumeral periarthritis, muscles and bones numbness are remarkable.
Experimental example 1
Summary: give mice collateral dredging bone strengthening pill of the present invention 0.3g/kg, 0.6g/kg, obviously suppress Oleum Tiglii induced mice ear swelling, capillary permeability increases due to the acid of antagonism acetic acid, thermostimulation and chemical twinge pain are all shown significant analgesia role, illustrate that it has good anti-inflammatory and analgesic effect.
Test material:
Collateral dredging bone strengthening pill of the present invention is provided lot number by western Shandong rheumatic osteopathia institute doctor Liu Jiling: 20010718.
Aspirin, Yongning, Jinan pharmaceutical Co. Ltd provides, lot number 20010301.
Evews lnad, Shanghai chemical reagent purchasing and supply station provides, lot number 9709231.
Mice, Kunming mouse, Shandong University's medical experiment animal center provides, the quality certification number: 900103.
The controlled wet hot-plate instrument of XMC-II, the Academy of Medical Sciences, Shandong instrument and equipment maintenance supply station product.
UIM II type ultra-violet and visible spectrophotometer, sino-america joint-venture Shanghai Lian Hua instrument plant produces.
Method and result:
1. to the influence of ear swelling due to the Oleum Tiglii: 48 of the male mices of 18～22g, be divided into 4 groups at random, per 12, give water and 3%, 1.5% logical Lip river bone strengthening pill suspension and aspirin 300mg/kgig respectively, be administered once every day for three days on end, last administration 30min, give 20ul 2% compound recipe Oleum Tiglii, be coated with the mouse right ear two sides, mountain diameter 9mm card punch is laid left and right sides auricle respectively behind the 4h, ten thousand/scales/electronic balance weighing, auris dextra weight-left ear weight=swelling degree, matched group-medicine group/matched group * 100%=presses down scorching rate.Result such as table 1.
Table 1 pair Oleum Tiglii causes the influence of mice bulge of the ear
The group Mus is counted swelling degree (mg) and presses down scorching rate (%)
Water matched group 12 26.81 ± 3.06
Collateral dredging bone strengthening pill 0.3g/kg 12 18.76 ± 4.26** 30.48 of the present invention
Collateral dredging bone strengthening pill 0.6g/kg 12 18.17 ± 5.21** 32.26 of the present invention
Aspirin 300mg/kg 12 18.46 ± 4.36** 31.16
* P＜0.01 time with
Medicine has the obvious suppression effect to Oleum Tiglii induced mice acute exudative inflammation, presses down scorching rate and reaches 30%.
2. the inhibition of Dichlorodiphenyl Acetate induced mice capillary permeability increase: the mice group administration is the same, for three days on end; The last administration, behind the 1h, every mice give 0.5% according to the blue tail vein injection 0.1ml/10g of Vickers, only give 0.6% glacial acetic acid 0.2ml/ immediately, take off cervical vertebra place mice behind the lumbar injection 30min, mouse peritoneal injection 6ml gently rubs mice thigh portion, washes repeatedly 3 times, extract abdominal cavity solution out, the centrifugal 10min of 3000rpm surveys OD value, result such as table 2 in 500nm.
The influence of table 2 pair nitric acid induced mice capillary permeability
The group Mus is counted swelling degree (mg) and presses down scorching rate (%)
Water matched group 12 0.324 ± 0.051
Collateral dredging bone strengthening pill 0.3g/kg 12 0.221 ± 0.063** 31.7 of the present invention
Collateral dredging bone strengthening pill 0.6g/kg 12 0.198 ± 0.057** 38.9 of the present invention
Aspirin 300mg/kg 12 0.206 ± 0.047** 36.4
The penetrating increase of collateral dredging bone strengthening pill Dichlorodiphenyl Acetate induced mice blood capillary of the present invention has the obvious suppression effect, reduces seepage discharge, thereby suppresses inflammatory reaction.
3. hold plate method analgesic experiment, through screening pain threshold＜30S, female mice 44, the random packet administration is the same, respectively at after the administration 1,2,4,6,8h surveys 55 ± 0.5 ℃ of mice pain thresholds on hot-plate instrument, knot is as table 3.
The analgesic activity of table 3 pair thermostimulation pain
Educate wealthy value (S)
Mus
Behind the group medicine
Before the number medicine
1h 2h 4h 6h 8h
Matched group 11 21.36 ± 7.21 22.11 ± 5.36 21.98 ± 4.86 22.63 ± 5.72 23.41 ± 7.28 21.89 ± 6.73
Collateral dredging bone strengthening 0.3g/kg 11 22.14 ± 5.6 28.54 ± 7.12* 44.25 ± 6.71*** 42.36 ± 6.71*** 36.14 ± 7.21* 24.51 ± 5.67 of the present invention
Collateral dredging bone strengthening 0.6g/kg 11 20.96 ± 7.01 26.27 ± 6.5 47.23 ± 6.41*** 51.21 ± 7.21*** 41.21 ± 6.13** 29.23 ± 7.82* of the present invention
Aspirin 300mg/kg 11 21.37 ± 6.27 29.36 ± 5.17 45.17 ± 5.31**, 36.27 ± 6.11*** 27.21 ± 5.12 23.51 ± 6.07
The collateral dredging bone strengthening pill has significant analgesia role, and 1h begins after the analgesic activity medication, and 2-4h does and be the strongest.
4. to the influence of mice pressure pain: the mice group administration is the same, surveys painful threshold value before the medicine by SMC-II type tenderness instrument earlier before the mice group, and pressure point is apart from tail class 1cm place, according to pain threshold grouping administration, give 3 days continuously, last administration 2h then, survey pain threshold again, result such as table 4.
The influence of table 4 pair mice tenderness pain threshold
Tenderness pain threshold (g)
Group Mus number
Behind the medicine prodrug
Water matched group 12 46.27 ± 5.6 47.61 ± 7.23
Collateral dredging bone strengthening pill 0.3g/kg 12 45.92 ± 6.27 56.91 ± 7.41 material of the present invention
Collateral dredging bone strengthening pill 0.6g/kg 12 46.11 ± 5.30 64.21 ± 5.67*** of the present invention
Aspirin 300mg/kg 12 46.31 ± 6.13 57.23 ± 6.17**
* * P＜0.001 collateral dredging bone strengthening pill of the present invention also has significant analgesia role to pressure pain.Brief summary:
The clinical preparation of the treatment rheumatic Bi syndrome that collateral dredging bone strengthening pill of the present invention is made up of expelling wind and dampness, removing obstruction in the collateral to relieve pain medicine, real this preparation of pharmacodynamic experiment checking has obvious anti-inflammatory analgesic, oral preparation obviously suppresses the acute exudative inflammation due to the inflammatory factor, increase the mice pain threshold, illustrate that this preparation has antiinflammatory, analgesic drug action.These effects are effect bases of this preparation wind-expelling pain-stopping.
Experimental example 2
Physical data
Have in 1256 examples of complete case record, male 680 people, women 576 people, the oldest 70 years old, minimum 18 years old, the course of disease is the longest 20 years, and was the shortest 1 month.All through clinical definite.
Criterion of therapeutical effect
Cure: transference cure, joint motion is normal, and lab testing is normal.Take a turn for the better: symptom is clearly better, and lab testing has improvement.Do not heal: symptom and lab testing do not have improvement.
Therapeutic outcome
Cure 847 examples in 1256 examples, 290 examples that take a turn for the better, 119 examples that do not heal, total effective rate is 94.92%.
Medical record for example
High * *, woman 48 years old, first visit on April 2 in 1997.Main suit: the big redness and swelling of joints pain of extremity 1 month.Patient's humidity of living, overwork, it is movable unfavorable to occur the big redness and swelling of joints pain of extremity before 1 month, sx after the clothes Chinese patent medicine chases after wind collaterals-activating capsule and Western medicine ibuprofen, feel stomach discomfort, appetite decline, spiritlessness and weakness after 10 days, red tongue, yellow and thin fur, stringy pulse.Look into: erythrocyte sedimentation rate 60mm/h, anti-" 0 " is normal, leukocyte 11 * 10
9/ L, hemoglobin 90g/L.Diagnosis: rheumatic arthritis.Give oral collateral dredging bone strengthening pill capsule, every day 3 times, each 4, external collateral dredging bone strengthening looses, and above-mentioned symptom disappears after 30 days.
Open * *, the man, 38 years old, went to a doctor in November, 1998.
The patient suffers from surplus the ankylosing spondylitis 10 year, waist sacrum and low-back pain are unbearably, companion moving obstacle, dysbasia, morning deadlock, soreness of the waist and knees, spiritlessness and weakness, spontaneous sweating, emaciated physique, lustreless complexion, pale tongue with thin fur is white, deep,thready and forceless pulse, erythrocyte sedimentation rate 64mm/h, gamma Globulin 21%, immunoglobulin 1gG, IgA increase, and lose self-viability half a year.
Differential diagnosis in tcm: deficiency of kidney-essence, deficiency of both the liver and kidney, the turbid numbness resistance of the stasis of blood.
Treatment: collateral dredging bone strengthening pill for oral administration, external collateral dredging bone strengthening looses, and lumbago is alleviated substantially after half a year.Check erythrocyte sedimentation rate 7mm/h, gamma Globulin 11%, IgG, IgA are normal, can orthobiosis and slight work.
Embodiment 1
Semen Strychni(processed) 60g Radix Aconiti Preparata 50g Radix Aconiti Kusnezoffii Preparata 50g Olibanum (processed) 25g Myrrha (processed) 25g
The parasitic 40g Radix Stephaniae Tetrandrae of Rhizoma Corydalis 100g Flos Carthami 30g 30g Rhizoma Gastrodiae 30g
Radix Ginseng 25g Radix Notoginseng 25g Scorpio 50g Scolopendra 20g Rhizoma Atractylodis 20g
Cortex Eucommiae 20g
Above-mentioned ten Six-element medical materials, Semen Strychni are concocted, fried stir-baking in sand all can, can't cross and give birth to or cross water.Radix Aconiti Preparata, Radix Aconiti Kusnezoffii Preparata dry after 3 hours with decocting in water again and are used as medicine.Olibanum, Myrrha processed with vinegar, with other drug routinely technology be ground into fine powder and make pill.
Embodiment 2
Semen Strychni(processed) 60g Radix Aconiti Preparata 50g Radix Aconiti Kusnezoffii Preparata 50g Olibanum (processed) 25g Myrrha (processed) 25g
The parasitic 40g Radix Stephaniae Tetrandrae of Rhizoma Corydalis 100g Flos Carthami 30g 30g Rhizoma Gastrodiae 30g
Radix Ginseng 25g Radix Notoginseng 25g Scorpio 50g Scolopendra 20g Rhizoma Atractylodis 20g
Cortex Eucommiae 20g
Above-mentioned ten Six-element medical materials, Semen Strychni are concocted, fried stir-baking in sand all can, can't cross and give birth to or cross water.Radix Aconiti Preparata, Radix Aconiti Kusnezoffii Preparata dry after 3 hours with decocting in water again and are used as medicine.Olibanum, Myrrha processed with vinegar, with other drug routinely technology be ground into fine powder and adorn capsule, every 0.4g No. 0.Consumption: each 5, every day 3 times.
Claims (3)
1, a kind of pharmaceutical composition for the treatment of rheumatism atrophic arthritis is characterized in that said composition is to be made by following crude drug:
Semen Strychni(processed) 20-100 weight portion Radix Aconiti Preparata 20-80 weight portion
Radix Aconiti Kusnezoffii Preparata 20-80 weight portion Olibanum (processed) 10-40 weight portion
Myrrha (processed) 10-40 weight portion Rhizoma Corydalis 200-300 weight portion
The parasitic 20-60 weight portion of Flos Carthami 10-50 weight portion
Radix Stephaniae Tetrandrae 10-50 weight portion Rhizoma Gastrodiae 10-50 weight portion
Radix Ginseng 10-40 weight portion Radix Notoginseng 10-40 weight portion
Scorpio 20-80 weight portion Scolopendra 8-30 weight portion
Rhizoma Atractylodis 8-30 weight portion Cortex Eucommiae 8-30 weight portion.
2, pharmaceutical composition according to claim 1 is characterized in that said composition is to be made by following crude drug:
Semen Strychni(processed) 60 weight portion Radix Aconiti Preparatas 50 weight portions
Radix Aconiti Kusnezoffii Preparata 50 weight portion Olibanum (processed)s 25 weight portions
Myrrha (processed) 25 weight portion Rhizoma Corydalis 100 weight portions
Parasitic 40 weight portions of Flos Carthami 30 weight portions
Radix Stephaniae Tetrandrae 30 weight portion Rhizoma Gastrodiaes 30 weight portions
Radix Ginseng 25 weight portion Radix Notoginseng 25 weight portions
Scorpio 50 weight portion Scolopendras 20 weight portions
The Rhizoma Atractylodis 20 weight portion Cortexs Eucommiae 20 weight portions.
3, pharmaceutical composition according to claim 1 and 2 is characterized in that also can add pharmaceutically acceptable excipient makes pill, tablet, oral liquid, capsule, granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03145967 CN1270755C (en) | 2003-07-18 | 2003-07-18 | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03145967 CN1270755C (en) | 2003-07-18 | 2003-07-18 | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1569085A true CN1569085A (en) | 2005-01-26 |
| CN1270755C CN1270755C (en) | 2006-08-23 |
Family
ID=34471565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03145967 Expired - Fee Related CN1270755C (en) | 2003-07-18 | 2003-07-18 | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1270755C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100408048C (en) * | 2005-07-14 | 2008-08-06 | 陈明东 | Capsule for treating rheumatism and rheumatoid diseases and scapulohumeral periarthritis and preparation method thereof |
| CN102526637A (en) * | 2012-03-12 | 2012-07-04 | 高永学 | Oral administration Chinese medicinal composition for treating rheumatism |
| CN104758647A (en) * | 2015-03-26 | 2015-07-08 | 华梅 | Traditional Chinese medicine wine for treating rheumatoid arthritis and preparation method of traditional Chinese medicine wine |
| CN113171431A (en) * | 2021-06-03 | 2021-07-27 | 绵阳德康疼痛医院 | Capsule for treating rheumatoid and preparation method thereof |
-
2003
- 2003-07-18 CN CN 03145967 patent/CN1270755C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100408048C (en) * | 2005-07-14 | 2008-08-06 | 陈明东 | Capsule for treating rheumatism and rheumatoid diseases and scapulohumeral periarthritis and preparation method thereof |
| CN102526637A (en) * | 2012-03-12 | 2012-07-04 | 高永学 | Oral administration Chinese medicinal composition for treating rheumatism |
| CN102526637B (en) * | 2012-03-12 | 2013-11-27 | 高永学 | Oral administration Chinese medicinal composition for treating rheumatism |
| CN104758647A (en) * | 2015-03-26 | 2015-07-08 | 华梅 | Traditional Chinese medicine wine for treating rheumatoid arthritis and preparation method of traditional Chinese medicine wine |
| CN113171431A (en) * | 2021-06-03 | 2021-07-27 | 绵阳德康疼痛医院 | Capsule for treating rheumatoid and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1270755C (en) | 2006-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101632827B (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
| CN1836720A (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN102058673B (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN1836725A (en) | Traditional Chinese medicine composition for treating arthritis and preparing method thereof | |
| CN1286502C (en) | Medicine for treating gout affection and its symptoms | |
| CN101167937A (en) | Traditional Chinese medicinal composition plaster for curing rheumatism or rheumatoid diseases and preparation method thereof | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN103845429A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN101032604A (en) | Chinese medicine preparation for curing vascular type headache | |
| CN1270755C (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN1840160A (en) | Powder for resisting hyperosteogeny | |
| CN1724014A (en) | Extractive of total saponin of clematis root, prepn. method and pharmaceutical use thereof | |
| CN1709288A (en) | Medicinal composition, and its preparing method and use | |
| CN100363043C (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN1899471A (en) | External use muscle relaxing preparation for treating traumatic injury and rheumatism stagnation pain and its preparing method | |
| CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN105362382A (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer and application thereof | |
| CN101590208B (en) | Medicament composition for treating rheumatoid arthritis, and preparation method thereof | |
| CN101028451A (en) | Chinese medicine for treating tic douloureux | |
| CN1051468C (en) | Capsule for curing rheumatism | |
| CN103933277A (en) | Tibetan drug for treating gout disease | |
| CN105250498A (en) | External composition for treating rheumatic arthritis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |